Guggenheim Reiterates Buy on Aralez Pharma (ARLZ) Ahead of PDUFA Date for Yosprala

August 15, 2016 7:35 AM EDT
Get Alerts ARLZ Hot Sheet
Price: $5.09 -2.3%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 30 | New: 24
Trade ARLZ Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Guggenheim reiterated a Buy rating and $12.00 price target on Aralez Pharmaceuticals (NASDAQ: ARLZ) ahead of the company's September 9th PDUFA date for Yosprala. Guggenheim is expecting approval and expects the company to launch the drug in 4Q16.

Analyst Louise Chen "We expect approval of Yosprala on its PDUFA date on 9/14. ARLZ has been preparing for the launch by expanding its cardiovascular salesforce and launching promotional efforts for its other cardiovascular drugs. If approved, we expect the company to launch the drug in 4Q16. We estimate peak sales of $200MM by '22, which we believe is not fully reflected in consensus expectations yet."

For an analyst ratings summary and ratings history on Aralez Pharmaceuticals click here. For more ratings news on Aralez Pharmaceuticals click here.

Shares of Aralez Pharmaceuticals closed at $4.69 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Louise Chen, PDUFA, Guggenheim

Add Your Comment